undamentalytics Newsletter
Sign in

Roivant Sciences Ltd. (ROIV) stock

Add to watchlist

Add holding +

NASDAQ: ROIV Nasdaq Biotechnology Next results ~November 9, 2026

D Fundamentals grade

Roivant Sciences Ltd. is a US-listed company in the biotechnology industry. Its financial year ends in March.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: every model's value for Roivant Sciences Ltd. is far from the share price, which usually points to a data problem (a merger, a share-count change, a one-off) rather than a bargain or a bubble.

Price vs value

Under review: free cash flow after stock pay is not positive. We'll show the comparison once resolved.

Roivant Sciences Ltd. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 12 selling1 purchase and 117 sales by directors and officers, last 12 monthsInsider trades
  • Funds293 adding, 181 cuttingOf 68 active managers that changed their stake, 39 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Roivant Sciences files

Where Roivant Sciences stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $8m, down 67.6% on a year earlier, faster than -71.6% a quarter earlier. That puts it 14 of 14 for growth among the pharmaceutical preparations companies we cover. Free-cash-flow margin fell to -10901.0% from -3695.9% a year earlier. Operating margin narrowed to -7914.8% from -5104.7%. Against its peers on growth, profitability, cash generation and balance sheet, it grades D. It passes 2 of our 2 financial-health checks.

Our model value for Roivant Sciences is under review, so past values are not shown until it is resolved.

Source: 10-Q filed August 6, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 9, 2026 (estimated)

Roivant Sciences Ltd.'s trailing-twelve-month revenue fell 67.6% year on year, with a free-cash-flow margin of -10901.0%. Where it stands out: change in share count of 0.6% ranks 29 of 156 biotechnology companies we cover. Where it lags: stock pay as % of revenue of 4611.4% ranks 176 of 179 biotechnology companies we cover.

Current signal Free cash flow diverging from earnings: TTM free cash flow grew 4.4% while net income grew 45.7%: a 41pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Net cash. Cash exceeds long-term debt by $1.2bn.
  • Beating expectations. Earnings per share beat the analysts' consensus estimate in each of the last four quarters.

Things to watch

  • Revenue shrinking. Revenue fell 67.6% over the last 12 months.
  • Loss-making. Operating margin is -7914.8%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 2810.0 points on a year ago.
  • Burning cash. Free cash flow was -10901.0% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 4611.4% of revenue, against a median of 19.2% for biotechnology companies we cover: a real cost that cash-flow figures leave out.
  • High sales multiple. The shares trade at 3354 times revenue while operating margins remain thin.

Latest results: FY2027 Q1

Filed August 6, 2026
Earnings per share
-$0.34 against an average estimate of -$0.36: beat by 4.9%
Revenue
$1m, down 33.5% on a year earlier
Share reaction
+5.0% in the first session after the results on August 6, 2026, against +0.5% for the S&P 500
Next report
November 9, 2026; average EPS estimate -$0.45

Roivant Sciences' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-2.8%
  • 1 week-0.4%
  • 1 month+0.5%
  • This year+65.4%
  • 1 year+79.5%
  • 5 years+352.0%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$7.5M
Operating margin
-7914.8%
Net margin
-3535.0%
EPS (TTM, diluted)
$-0.38

Growth

Revenue growth
−67.6%
Change in growth rate
+4.0 pts
Share count change
+0.6%

Cash

Free cash flow (TTM)
-$821M
FCF margin
-10901.0%
Stock pay % of revenue
4611.4%

Earnings

Last results
August 6, 2026

News & updates

Updated November 2, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Our research
  2. Insider trade
  3. Announcement
  4. Insider trade
  5. Insider trade
  6. Shareholder vote
  7. Announcement
  8. Announcement
  9. Insider trade
  10. Announcement
  11. Insider trade
  12. Insider trade
  13. Insider trade
  14. Insider trade
  15. Insider trade
  16. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Roivant Sciences Ltd. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: free cash flow after stock pay is not positive.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Roivant Sciences Ltd. as an operating company, with every model that fits that kind of business. Cost of equity 9.3%: the 10-year Treasury yield (4.9%) plus a beta of 0.97 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$6.8 ~$5.2–$8.4 Left out: out of range vs price (0.19x)
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: This model is withheld pending its input or assumption review.
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: This model is withheld pending its input or assumption review.
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: This model is withheld pending its input or assumption review.
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$1.7 ~$1.8–$6.7 Left out: out of range vs price (0.05x)
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: This model is withheld pending its input or assumption review.
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Roivant Sciences Ltd. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 202120222023202420252026Now
Share price$9.78$4.94$7.38$10.54$10.09$27.70$35.89
Market value$6.2bn$3.3bn$5.3bn$8.8bn$7.3bn$19.2bn$25.3bn
+ Net debt (− = net cash)−$1.9bn−$1.9bn−$1.3bn−$6.1bn−$2.7bn−$1.4bn−$1.2bn
Enterprise value$4.3bn$1.5bn$4.0bn$2.7bn$4.6bn$17.8bn$24.0bn
Multiples
Price / sales n/m59.8x166.8xn/mn/mn/mn/m
Price / earnings ———2.0x———
Price / free cash flow ———————
EV / EBITDA ———0.6x———

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

12 /100

Weak moat

How hard Roivant Sciences's competitive advantage looks for rivals to wear away, judged from 6 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -23.0% of total assets over 6 years.

  • Durability 10 / 20

    Operating margin has been a median -3280.5%; its worst year was -7914.8%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 6 years, at a median -1965.1% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (17 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 9, 2026, before the open. Analysts expect revenue of $4m and EPS of −$0.45 (range −$0.59 to −$0.35) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$1.58 −47% $52m +531%
Next −$1.72 −9% $410m +688%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +5.7% on 90 days ago. In the last 30 days, 0 analysts raised Roivant Sciences Ltd.'s forecast and 3 cut it.

Consensus EPS forecast Roivant Sciences Ltd., last 90 days
−$2.00 −$1.50 −$1.00 −$0.50 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$1.50 Current fiscal year, 60 days ago: −$1.50 Current fiscal year, 30 days ago: −$1.58 Current fiscal year, 7 days ago: −$1.58 Current fiscal year, Now: −$1.58 −$1.58 Next fiscal year, 90 days ago: −$1.56 Next fiscal year, 60 days ago: −$1.72 Next fiscal year, 30 days ago: −$1.72 Next fiscal year, 7 days ago: −$1.72 Next fiscal year, Now: −$1.72 −$1.72

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$1.50−$1.56
60 days ago −$1.50−$1.72
30 days ago −$1.58−$1.72
7 days ago −$1.58−$1.72
Now −$1.58−$1.72

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.36 −$0.34 +4.9%
Mar 2026 −$0.35 −$0.32 +9.3%
Dec 2025 −$0.31 −$0.24 +23.0%
Sept 2025 −$0.30 −$0.28 +9.3%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 6, 2026

No numeric guidance in Roivant Sciences Ltd.'s latest earnings release (filed August 6, 2026). Some companies give their outlook only on the earnings call.

Analyst recommendations

13 analysts, Oct 2026
Buy1185%
Hold215%
Sell00%

Monthly trend

  1. Oct 202629213
  2. Sep 2026210113
  3. Aug 202629112
  4. Jul 202629112

Counts of recommendations published by analysts covering Roivant Sciences Ltd., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
7.6%
of tradable shares
Days to cover
5.65
at average volume
Short interest, 1 month
+11%
to October 15, 2026
Held by institutions
78%
of shares
Held by insiders
21.4%
of shares
Employees
721
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months +79.5%

$19.99 on October 31, 2025 to $35.89

ThenNowEffect
Revenue (last 12 months) $23m $8m −67.6%
P/S multiple n/m n/m +456.9%
Share count 700m 704m −0.6%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

Last 3 years +286.7%

$9.28 on November 3, 2023 to $35.89

ThenNowEffect
Revenue (last 12 months) $49m $8m −84.6%
P/S multiple 138.5x n/m +2322.7%
Share count 729m 704m +3.5%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
ROIV−1%−21%+41%+5%+83%+65%
Industry peers (median)−36%−57%−18%−29%−5%−27%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
ROIV50%33%67%58%67%64%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
ROIV−45%−72%−37%−16%−25%−20%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since December 8, 2020: 79% from December 20, 2021 to May 12, 2022. Getting back needed a 381% gain, reached on September 10, 2025, 1217 days after the low.

Price behaviour

52-week range
$19.60 – $41.81
From 52-week high
−14.2%
vs 50-day average
−2.0%
vs 200-day average
+13.7%
Volatility (1 year)
47%
Beta vs S&P 500
1.06

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
10 up, 2 down
typical move ±6.1%
After a week
8 up, 4 down
typical move ±5.9%
After a month
9 up, 3 down
typical move ±9.6%
Results releasedNext dayS&P 500 next day5 days21 days
August 6, 2026 +5.0% +0.5% +4.9% +1.0%
May 20, 2026 +9.5% +1.2% +5.9% +10.8%
April 2, 2026 +0.1% +0.6% +1.3% +1.9%
February 6, 2026 +30.9% +2.4% +25.1% +40.5%
November 10, 2025 +1.4% +1.8% −0.3% −1.8%
August 11, 2025 +0.7% +0.9% +2.8% +19.8%
May 29, 2025 +3.5% +0.3% +5.5% +6.1%
February 10, 2025 −3.7% +0.8% −1.9% −2.7%
November 12, 2024 +1.2% −0.3% −4.2% +0.6%
August 8, 2024 +9.3% +2.8% +11.2% +22.9%
May 30, 2024 −3.4% +0.2% −1.0% +0.9%
February 13, 2024 +4.1% −0.5% +6.2% −5.9%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Roivant Sciences Ltd. in five measures

Fundamentals grade D
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Roivant Sciences Ltd.
$0 $20M $40M $60M FY24 Q2 FY25 Q1 FY25 Q4 FY27 Q1 Revenue (TTM), FY24 Q2: $40M Revenue (TTM), FY24 Q3: $38.5M Revenue (TTM), FY24 Q4: $49.9M Revenue (TTM), FY25 Q1: $36.2M Revenue (TTM), FY25 Q2: $37M Revenue (TTM), FY25 Q3: $30.5M Revenue (TTM), FY25 Q4: $29.1M Revenue (TTM), FY26 Q1: $23.2M Revenue (TTM), FY26 Q2: $20.3M Revenue (TTM), FY26 Q3: $13.3M Revenue (TTM), FY26 Q4: $8.3M Revenue (TTM), FY27 Q1: $7.5M $7.5M

Source: SEC EDGAR filings. Retrieved October 20, 2026.

View chart data
Period Revenue (TTM)
FY24 Q2 $40M
FY24 Q3 $38.5M
FY24 Q4 $49.9M
FY25 Q1 $36.2M
FY25 Q2 $37M
FY25 Q3 $30.5M
FY25 Q4 $29.1M
FY26 Q1 $23.2M
FY26 Q2 $20.3M
FY26 Q3 $13.3M
FY26 Q4 $8.3M
FY27 Q1 $7.5M
Revenue growth, TTM YoY Roivant Sciences Ltd.
-100% -50% 0% 50% 100% FY24 Q2 FY25 Q1 FY25 Q4 FY27 Q1 Revenue growth, TTM YoY, FY24 Q2: -20.8% Revenue growth, TTM YoY, FY24 Q3: -10.8% Revenue growth, TTM YoY, FY24 Q4: 58.1% Revenue growth, TTM YoY, FY25 Q1: -25.8% Revenue growth, TTM YoY, FY25 Q2: -7.3% Revenue growth, TTM YoY, FY25 Q3: -20.7% Revenue growth, TTM YoY, FY25 Q4: -41.7% Revenue growth, TTM YoY, FY26 Q1: -35.9% Revenue growth, TTM YoY, FY26 Q2: -45.1% Revenue growth, TTM YoY, FY26 Q3: -56.4% Revenue growth, TTM YoY, FY26 Q4: -71.6% Revenue growth, TTM YoY, FY27 Q1: -67.6% -67.6%

Source: SEC EDGAR filings. Retrieved October 20, 2026.

View chart data
Period Revenue growth, TTM YoY
FY24 Q2 -20.8%
FY24 Q3 -10.8%
FY24 Q4 58.1%
FY25 Q1 -25.8%
FY25 Q2 -7.3%
FY25 Q3 -20.7%
FY25 Q4 -41.7%
FY26 Q1 -35.9%
FY26 Q2 -45.1%
FY26 Q3 -56.4%
FY26 Q4 -71.6%
FY27 Q1 -67.6%
Operating margin (TTM) Roivant Sciences Ltd.
-10000% 0% 10000% 20000% FY24 Q2 FY25 Q1 FY25 Q4 FY27 Q1 Operating margin (TTM), FY24 Q2: -2087.6% Operating margin (TTM), FY24 Q3: 12146.5% Operating margin (TTM), FY24 Q4: 8886.6% Operating margin (TTM), FY25 Q1: 12712.6% Operating margin (TTM), FY25 Q2: 12083.8% Operating margin (TTM), FY25 Q3: -3033.0% Operating margin (TTM), FY25 Q4: -3453.3% Operating margin (TTM), FY26 Q1: -5104.7% Operating margin (TTM), FY26 Q2: -5659.4% Operating margin (TTM), FY26 Q3: -9130.5% Operating margin (TTM), FY26 Q4: -6235.7% Operating margin (TTM), FY27 Q1: -7914.8% -7914.8%

Source: SEC EDGAR filings. Retrieved October 20, 2026.

View chart data
Period Operating margin (TTM)
FY24 Q2 -2087.6%
FY24 Q3 12146.5%
FY24 Q4 8886.6%
FY25 Q1 12712.6%
FY25 Q2 12083.8%
FY25 Q3 -3033.0%
FY25 Q4 -3453.3%
FY26 Q1 -5104.7%
FY26 Q2 -5659.4%
FY26 Q3 -9130.5%
FY26 Q4 -6235.7%
FY27 Q1 -7914.8%
FCF margin (TTM) Roivant Sciences Ltd.
-15000% -10000% -5000% 0% FY24 Q2 FY25 Q1 FY25 Q4 FY27 Q1 FCF margin (TTM), FY24 Q2: -2129.8% FCF margin (TTM), FY24 Q3: -2180.3% FCF margin (TTM), FY24 Q4: -1537.8% FCF margin (TTM), FY25 Q1: -1960.5% FCF margin (TTM), FY25 Q2: -2108.7% FCF margin (TTM), FY25 Q3: -2555.4% FCF margin (TTM), FY25 Q4: -2905.2% FCF margin (TTM), FY26 Q1: -3695.9% FCF margin (TTM), FY26 Q2: -3858.4% FCF margin (TTM), FY26 Q3: -5761.5% FCF margin (TTM), FY26 Q4: -9183.5% FCF margin (TTM), FY27 Q1: -10901.0% -10901.0%

Source: SEC EDGAR filings. Retrieved October 20, 2026.

View chart data
Period FCF margin (TTM)
FY24 Q2 -2129.8%
FY24 Q3 -2180.3%
FY24 Q4 -1537.8%
FY25 Q1 -1960.5%
FY25 Q2 -2108.7%
FY25 Q3 -2555.4%
FY25 Q4 -2905.2%
FY26 Q1 -3695.9%
FY26 Q2 -3858.4%
FY26 Q3 -5761.5%
FY26 Q4 -9183.5%
FY27 Q1 -10901.0%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2021 Mar 2021 2022 Mar 2022 2023 Mar 2023 2024 Mar 2024 2025 Mar 2025 2026 Mar 2026 LTM Jun 2026
Income
Revenue 24 55 32 33 29 8 8
EBITDA — −1,346 −888 4,519 −989 −512 −593
Operating income −1,071 −1,352 −907 4,497 −1,003 −515 −596
Net income −809 −845 −1,009 4,349 −172 −300 −266
Diluted EPS −$1.28 −$1.26 −$1.42 $5.23 −$0.24 −$0.54 −$0.38
Growth (year on year)
Revenue — +132.3% −43.0% +3.8% −11.2% −71.6% −67.6%
EBITDA — — — — −121.9% — —
Operating income — — — — −122.3% — —
Net income — — — — −104.0% — —
Diluted EPS — — — — −104.6% — —
Margins
EBITDA margin — <−999% <−999% >999% <−999% <−999% <−999%
Operating margin <−999% <−999% <−999% >999% <−999% <−999% <−999%
Net margin <−999% <−999% <−999% >999% −592.0% <−999% <−999%
Free-cash-flow margin <−999% <−999% <−999% <−999% <−999% <−999% <−999%
Cash flow
Cash from operations −552 −678 −843 −765 −839 −750 −816
Capital spending 6 17 13 1 5 8 5
Free cash flow −558 −695 −856 −767 −844 −759 −821
Stock-based pay 85 565 218 200 289 346 347
Free cash flow after stock pay −643 −1,260 −1,074 −966 −1,133 −1,105 −1,168
Balance sheet
Cash 2,055 2,060 1,677 6,495 2,715 1,419 1,248
Total debt 170 210 376 431 — 0 0
Net debt (negative = net cash) −1,885 −1,850 −1,301 −6,064 −2,715 −1,419 −1,248
Diluted shares 630m 670m 713m 831m 725m 694m 704m
Returned to shareholders
Buybacks — — 0 0 1,293 — —
Total returned — — 0 0 1,293 — —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 2 checks passed · June 30, 2026
What it owns · $5.3bn
Short-term assets $4.7bnLonger-term assets $564m
What it owes, and who funded it · $4.6bn
Short-term liabilities $284mLonger-term liabilities $101mShareholders' equity $4.2bn
  • Short-term assets cover short-term liabilities $4.7bn of assets due within a year against $284m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $4.7bn short-term assets against $101m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Roivant Sciences Ltd.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

FY2026 Q3 TTM
Buybacks (TTM)
$504M
Returned to shareholders
-66%
of free cash flow
Diluted share count
+0.6%
year over year
Total shareholder yield
1.9%
dividends 0.0% + buybacks 1.9% of market value
R&D spending
9704.0%
of revenue

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated ROIV EVAX ADAG TCRX COYA ACRS Median
Revenue, last 12 months $8m $8m $8m $7m $8m $8m $56m
Revenue growth, last 12 months −67.6% 125.1% >999% 2.2% >999% −51.0% 12.6%
Revenue growth, 3-year average −46.4% — — −24.3% — −35.9% 13.7%
Revenue growth, latest quarter −33.5% — — −65.8% 49.0% −8.3% 10.2%
Operating margin <−999% −122.7% −279.5% <−999% −288.7% <−999% −189.4%
Operating margin, 3-year average −102.3% — — <−999% <−999% −711.4% −363.5%
Net margin <−999% −102.4% −229.6% <−999% −270.2% −921.5% −169.8%
Cash from operations / revenue <−999% −88.0% −204.1% <−999% −196.1% −755.1% −168.0%
Free-cash-flow margin <−999% −88.2% −204.3% <−999% −196.3% −756.5% −162.4%
Free-cash-flow margin, 3-year average <−999% — — <−999% <−999% −339.9% −310.0%
Stock pay / revenue >999% 4.1% 48.8% 138.4% 66.3% 141.8% 20.0%
Change in share count 0.6% 497.3% 4.8% 4.1% 22.4% 25.5% 8.2%

Median of all 184 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

184 biotechnology companies
Measure Company Peer median Rank
Revenue growth Growth -67.6% 12.6% 152 of 172
Change in growth rate Growth +4.0pp -0.1pp 57 of 172
Operating margin Profitability -7914.8% -189.4% 163 of 175
Net margin Profitability -3535.0% -157.3% 160 of 180
Free-cash-flow margin Cash generation -10901.0% -145.4% 169 of 176
Stock pay as % of revenue Cash generation 4611.4% 19.2% 176 of 179
Change in share count Balance sheet 0.6% 7.9% 29 of 156

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$20B
Institutions reporting
494
Shares held vs prior quarter
▲ 6.3%
Positions opened / closed
92 / 41

Top buyers and sellers, Q2 2026: 293 institutions bought and 181 sold ; the biggest buyer was Assenagon Asset Management S.A (+9.6M shares) and the biggest seller Morgan Stanley (−9.2M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
FMR LLC $2.9B 81.0M 14.4% ▲ 3.9%
Blackrock, Inc. $1.7B 48.2M 8.6% ▲ 9.0%
Morgan Stanley $1.5B 42.6M 7.6% ▼ 17.8%
Qvt Financial LP $840M 23.7M 4.2% ▼ 5.7%
Vanguard Capital Management LLC $783M 22.1M 3.9% ▲ 7.0%
Vanguard Portfolio Management LLC $766M 21.6M 3.8% ▲ 9.1%
Goldman Sachs Group Inc $657M 18.6M 3.3% ▲ 67.0%
State Street Corp $630M 17.8M 3.2% ▲ 9.9%
UBS Group AG $618M 17.5M 3.1% ▼ 22.8%
Assenagon Asset Management S.A. $592M 16.7M 3.0% ▲ 136.4%
Farallon Capital Management, L.L.C. $506M 14.3M 2.5% ▲ 47.9%
Geode Capital Management, LLC $426M 11.7M 2.1% ▲ 14.7%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Roivant Sciences Ltd.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $350M 1 trade by 1 insider, last 12 months Insider sales History → $892M 117 trades by 12 insiders · 18% under pre-set plans
Net ▼ $542M net selling
Insider Date Trade Shares Price Value
Venker Eric President & Immunovant CEO October 28, 2026 Sell pre-set plan 200,000 $36.59 $7.3M
Venker Eric President & Immunovant CEO October 20, 2026 Sell pre-set plan 14,144 $35.42 $500,980
Venker Eric President & Immunovant CEO October 20, 2026 Sell pre-set plan 185,856 $35.09 $6.5M
Epperly Melissa B, Director October 1, 2026 Sell pre-set plan 900 $36.57 $32,913
Epperly Melissa B, Director October 1, 2026 Sell pre-set plan 16,850 $36.08 $607,948
Venker Eric President & Immunovant CEO September 30, 2026 Sell pre-set plan 200,000 $36.62 $7.3M
Fitzgerald Meghan Director September 15, 2026 Sell pre-set plan 4,712 $39.68 $186,972
Fitzgerald Meghan Director September 15, 2026 Sell pre-set plan 400 $40.45 $16,180
Epperly Melissa B, Director September 15, 2026 Sell pre-set plan 600 $40.38 $24,228
Epperly Melissa B, Director September 15, 2026 Sell pre-set plan 4,338 $39.65 $172,002
Fitzgerald Meghan Director September 8, 2026 Sell pre-set plan 20,000 $39.90 $798,000
Venker Eric President & Immunovant CEO August 28, 2026 Sell pre-set plan 33,818 $36.44 $1.2M

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 4 trades and filings

No trades in Roivant Sciences Ltd. disclosed in the last 12 months; 4 earlier trades on record.

  • Lisa C. McClain(R-MI 9):Sale (full), $1,001 - $15,000, traded October 31, 2025, filed November 21, 2025
  • Lisa C. McClain(R-MI 9):Sale (full), $1,001 - $15,000, traded October 30, 2025, filed November 21, 2025
  • Lisa C. McClain(R-MI 9):Purchase, $1,001 - $15,000, traded October 30, 2025, filed November 21, 2025

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

Next expected around October 28, 2026 estimated from the company's past filing pattern, not announced

  • August 6, 2026
  • May 20, 2026
  • April 2, 2026
  • February 6, 2026
  • November 10, 2025
  • August 11, 2025

Recent SEC filings

Data status

When each part of this page on Roivant Sciences Ltd. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Roivant Sciences Ltd. in brief

What does Roivant Sciences Ltd. do?
Roivant Sciences Ltd. is a US-listed company in the biotechnology industry. Its financial year ends in March.
What is Roivant Sciences Ltd.'s stock ticker?
Roivant Sciences Ltd. trades under the ticker ROIV on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Roivant Sciences Ltd.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Roivant Sciences Ltd. reported revenue of $7.5M, 67.6% lower than a year earlier, according to its SEC filings.
What is Roivant Sciences Ltd.'s free cash flow?
Roivant Sciences Ltd.'s free-cash-flow margin is -10901.0% of revenue over the trailing twelve months, ranking 169 of the 176 biotechnology companies we cover.
Who are Roivant Sciences Ltd.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are FMR LLC, Blackrock, Inc. and Morgan Stanley. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Is Roivant Sciences Ltd. buying back stock, and does it pay a dividend?
Roivant Sciences Ltd. spent $504M on share repurchases over the trailing twelve months, and its diluted share count still rose 0.6% over the year.
What is Roivant Sciences Ltd.'s market cap?
On November 2, 2026, Roivant Sciences Ltd.'s market capitalisation was about $25.3B and net debt of -$1.2B. Market figures come from third-party market data and may be delayed.
Who are Roivant Sciences Ltd.'s competitors?
In our Biotechnology peer group, the companies closest to Roivant Sciences Ltd. are Evaxion A/s, Adagene Inc., Tscan Therapeutics, Inc., Coya Therapeutics, Inc. and Aclaris Therapeutics, Inc. The side-by-side comparison below sets their revenue, margins and growth against Roivant Sciences Ltd.'s.
Are insiders buying or selling Roivant Sciences Ltd. stock?
Over the last 12 months, Roivant Sciences Ltd.'s directors and officers reported 1 open-market purchases and 117 sales on Form 4. The insider trading page charts every trade.
When is Roivant Sciences Ltd.'s next earnings date?
Around November 9, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Roivant Sciences Ltd. announces its own schedule.